Skip to main content

Table 3 Patient characteristics and the incidence of SSI

From: Clinical study of a new skin antiseptic olanexidine gluconate in gastrointestinal cancer surgery

Patient characteristics SSI− (n = 269) SSI+ (n = 12) P value
Mean age (range) 72.9 ± 10.6 77.4 ± 11.3 0.151
Gender 0.37
 M 155 (57.6%) 9 (75.0%)  
 F 114 (42.4%) 3 (25.0%)  
Mean BMI ± SD 22.2 ± 3.5 22.9 ± 3.9 0.485
Diabetes mellitus (%) 78 (29.0%) 7 (58.3%) 0.0489
Albumin ± SD 3.89 ± 0.53 3.71 ± 0.52 0.244
Respiratory disease 43 (16.0%) 4 (33.3%) 0.122
Anticoagulant 28 (17.1%) 5 (45.5%) 0.032
ASA 0.0434
 1.2 207 (77.0%) 6 (50.0%)  
 3 62 (23.0%) 6 (50.0%)  
Mean operation time ± SD 300.1 ± 110.0 339.7 ± 191.8 0.242
Bleeding (ml) 128.4 ± 222.6 188.6 ± 340.0 0.373
Approach 1
 Open 127 (50.0%) 6 (50.0%)  
 Laparoscopy 127 (50.0%) 6 (50.0%)  
Transfusion 6 (2.2%) 0 (0%) 1
Use of olanexidine 217 (90.4%) 6 (50.0%) 0.02
Primary lesion 0.118
 Stomach 82 (34.2%) 1 (8.3%)  
 Colon 187 (65.8%) 11 (91.7%)  
Tumor size (cm) 4.65 ± 2.56 4.25 ± 2.13 0.595
Stage 0.543
 0, I, II 180 (66.9%) 7 (58.3%)  
 III, IV 89 (33.1%) 5 (41.7%)  
Leakage 9 (100%) 0 (0%) 1
Complication except SSI 63 (23.5%) 6 (50.0%) 0.0782
Adverse skin reaction (all) 7 (2.6%) 0 (0%) 1